Alkermes Plc Stock News
$28.78
2.61%
today
Nasdaq,
Dec 30, 10:00 pm CET
Alkermes Plc Stock News
Neutral
PRNewsWire
●
about one month ago
DUBLIN , Nov. 25, 2024 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that management will participate in two upcoming investor conferences. 7th Annual Evercore ISI HealthCONx Conference Date/Time: Tuesday, Dec. 3, 2024 at 10:25 a.m.
Positive
Seeking Alpha
●
about one month ago
Alkermes has shifted from royalty-based revenues to proprietary product sales, driven by strong growth in Lybalvi, Vivitrol, and Aristada. ALKS 2680, a Phase 2 orexin-2 receptor agonist for narcolepsy and hypersomnia, represents a transformative opportunity in a $7.3 billion market by 2032. With $908.9 million in liquidity and a positive cash flow of $73.3 million in Q3, Alkermes can effectivel...
Neutral
Investors Business Daily
●
about one month ago
The top five biotech stocks today have several commonalities. Among them are strong ratings.
Neutral
PRNewsWire
●
about 2 months ago
DUBLIN , Nov. 11, 2024 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that management will participate at two upcoming investor conferences. Stifel Healthcare Conference Date/Time: Monday, Nov. 18, 2024 at 8:35 a.m.
Neutral
PRNewsWire
●
about 2 months ago
– 12 Poster Presentations Showcase Research in Schizophrenia, Bipolar I Disorder and Narcolepsy – – Results Presented From Real-World Retrospective Study of Healthcare Resource Utilization and Treatment Patterns in Patients With Schizophrenia or Bipolar I Disorder Following Initiation of LYBALVI®(olanzapine and samidorphan) – DUBLIN , Nov. 7, 2024 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) to...
Neutral
Seeking Alpha
●
2 months ago
Alkermes plc (NASDAQ:ALKS ) Q3 2024 Earnings Conference Call October 24, 2024 8:00 AM ET Company Participants Sandra Coombs - Senior Vice President of Investor Relations and Corporate Affairs Richard Pops - CEO Todd Nichols - Chief Commercial Officer Blair Jackson - Chief Operating Officer. Conference Call Participants Joseph Thome - TD Cowen Umer Raffat - Evercore Paul Matteis - Stifel Charles...
Neutral
PRNewsWire
●
2 months ago
— Third Quarter Revenues of $378.1 Million — — Net Sales of Proprietary Products Increased Approximately 18% Year-Over-Year — — GAAP Net Income from Continuing Operations of $92.8 Million and Diluted GAAP Earnings per Share from Continuing Operations of $0.56 — — Company Reiterates 2024 Financial Expectations — DUBLIN , Oct. 24, 2024 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today reported fi...
Neutral
PRNewsWire
●
2 months ago
DUBLIN , Oct. 17, 2024 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m.
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
